Navigation Links
Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion
Date:7/10/2014

tp://www.evoderma.com" >EvoDerma
EvoDerma Inc. strives to provide cutting-edge skin care and hair removal products for use in the privacy and convenience of the home. Its innovative research and development department is continuously working to offer consumers professional-grade aesthetic products for home use. The ELITE AMP hair removal device, evoDerma’s flagship IPL product, is a testament to the company’s commitment to quality, safety and efficiency.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12009318.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Introducing a New, Easy Way for Industrial Businesses to Join the Online Conversation
2. Introducing version 4.0 of ezColony™ - Transgenic Animal Colony Management Software
3. iLuv Introducing NFC & Qi-Certified Technology to Bluetooth Speaker Lineup at 2013 CES
4. Impact with Martin Sheen Introducing Audiences to the Next Generation of Environmental Custodians
5. Express Diagnostics Introducing New Products and Expanded Catalog of Drug Tests at the 2013 AACC Clinical Lab Expo
6. Introducing a Personal Injury Chiropractor in Tampa Florida That is Utilizing the Latest Treatment Technology in the Industry, Courtesy of Elan Wellness Center
7. Introducing the BioProcess International Online Poster Hall 2014
8. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... April 23, 2015  Veracyte, Inc. (NASDAQ: VCYT ) ... agreement to sell approximately $40 million of its common ... investors will purchase an aggregate of 4,907,975 shares of ... share, the closing stock price on April 22, 2015. ... investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital ...
(Date:4/23/2015)... Irvine, CA (PRWEB) April 23, 2015 ... research leader in Personalized Medicine, is excited to ... Medication Response profile . This profile assesses 62 ... and provide dosing information for commonly prescribed non-opioid ... gabapentin (brand name Neurontin), alprazolam (brand name Xanax) ...
(Date:4/23/2015)... YORK, NY , April 23, 2015 /PRNewswire/ - ... issued an Executive Informational Overview ® (EIO) on ... full 52-page report is available on Crystal Research Associates, ... as on Aeterna Zentaris, website at www.aezsinc.com . ... transitioning into a specialty biopharmaceutical company in oncology, endocrinology, ...
(Date:4/22/2015)... , April 23, 2015  The Heinz Family ... th Heinz Awards, which will present unrestricted ... Americans for their creativity and determination in finding ... This year,s recipients include a prolific ... modern-day life and personal relationships; two former Marines ...
Breaking Biology Technology:Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6
... Scientists engaged in biological research and drug discovery are ... BioInformatics, LLC ( www.gene2drug.com ), the premier research ... released preliminary data from the company,s newest report ... Science Suppliers. In this report, we set out ...
... LOUIS, Feb. 11 Sigma-Aldrich, a leading Life,Science and High ... by 6% to $0.68 from $0.64 in the same quarter ... $510 million in the fourth quarter 2008 declined by 4%,compared ... fourth,quarter grew 3% from a year ago. Fourth quarter organic ...
... Development for Chronic Pain IndicationsLA JOLLA, Calif., Feb. ... TPTX ) today announced that oral administration of ... and well-tolerated in healthy male and female subjects ... successful completion of this Phase I trial demonstrating ...
Cached Biology Technology:Life Science Labs Reacting to the Economic Crisis 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 3Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 4Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 5Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 6Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 7Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 8Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 9Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 10Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 11Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 12Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 13First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore ... key protein linked to stem cell-like behavior in terminal-stage ... drugs that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , ...
... to reduce by more than half the time it takes ... researchers in Penn State,s College of Agricultural Sciences. The finding ... foodborne illness, allowing epidemiological investigators to identify the exact strains ... more quickly find -- and eliminate -- the source of ...
... long been used for various purposes, like cleaning wastewater at ... handcrafted wickerwork, as means of nutrition and, in traditional medicine, ... Fraunhofer Institute for Building Physics IBP in Valley now want ... to wit, for the insulation of outer walls or ...
Cached Biology News:Singapore research team identifies new drug target in deadly form of leukemia 2Researchers develop a faster method to identify Salmonella strains 2Researchers develop a faster method to identify Salmonella strains 3Using cattails for insulation 2Using cattails for insulation 3
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... cell lines in combination with the ... parameters. Nucleofector Kits are only functional ... Different cell lines can be transfected ... and viabilities are given in brackets ...
... BUF040A is a diluent that is designed ... antibodies which are paired with a mouse monoclonal ... contains rabbit and mouse proteins to prevent non-specific ... • This buffer may be ...
... your protein is in solution or in a ... mass spectrometry. Proteins will be digested to produce ... of the peptides are determined by MALDI-TOF, and ... peaks (peptides) from MALDI-TOF will be determined by ...
Biology Products: